ع
Insider Monkey reported that Moderna Inc. conducted senior-level investment discussions with United Arab Emirates authorities this week, a development that drove the company’s shares to their highest closing price since 2022. The analysis highlighted the potential for partnerships in vaccine manufacturing and oncology therapies as key topics during the meetings held in Abu Dhabi. Moderna has maintained a presence in the Middle East through regulatory approvals for its respiratory syncytial virus vaccine in several Gulf states, according to company announcements distributed via Business Wire.
The stock advance added nearly 15 percent to Moderna’s share price in one session, pushing its market value above levels recorded during the later stages of the COVID-19 vaccine rollout, Refinitiv market data showed on September 24, 2026. This rebound occurs as the firm prepares to present late-breaking melanoma trial results at the European Society for Medical Oncology Congress, an event the company detailed in a September 21, 2026 press release. A Marketscreener summary of the presentation schedule noted that positive efficacy data could further strengthen investor confidence in Moderna’s oncology pipeline.
Insider Monkey’s assessment drew on recent regulatory filings that revealed Moderna’s strategy to secure regional manufacturing deals to offset declining COVID-19 product sales. The publication estimated that a successful UAE agreement could contribute several hundred million dollars in annual revenue once facilities become operational. Bloomberg Intelligence previously projected that mRNA technology investments across the Gulf Cooperation Council states would exceed $1.5 billion by 2028, citing sovereign wealth funds’ growing focus on health security.
Moderna reported entering 2025 with two approved products, Spikevax and mRESVIA, after posting full-year 2024 revenues that stabilized following the post-pandemic drop, according to a February 2025 Newswire release summarizing its fiscal results. The company has since opened an mRNA manufacturing site in Australia and advanced similar projects in the United Kingdom, Pharmaceutical Technology documentation on those facilities indicated. UAE officials have expressed interest in replicating such infrastructure locally to support national pandemic preparedness goals outlined in government economic diversification plans.
Trading activity surged to more than twice the average daily volume as the investment talks circulated among market participants, Nasdaq statistics compiled by financial terminals confirmed. Analysts covering the stock have raised price targets in recent weeks, with consensus estimates placing fair value approximately 20 percent higher than the pre-announcement level. An Al Majalla article published on September 3, 2026, connected Moderna’s cancer treatment progress to increased sovereign investment interest from the UAE, describing it as part of a broader ecosystem-building effort in regional healthcare innovation.
